EDIT vs SPGI · rev $32.3M vs P/E 27, rev $15.34B
Editas Medicine Inc (EDIT) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
EDIT currently screens at market cap $375.2M. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the EDIT and SPGI stock pages for the full models.
Not investment advice.